SCHEMBL3292829

SCHEMBL3292829

Cc1c(Cl)cccc1S(=O)(=O)Nc1nc2ccccc2nc1OCc1ccc(Cl)c(OCC2CCN(C)CC2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR4 P51679 5/20 0.40
HRH4 Q9H3N8 2/20 0.39
HSD11B1 P28845 3/20 0.38
HSD17B1 P14061 1/20 0.38
HSD17B2 P37059 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
EGFR P00533 2/20 0.38
AKT1 P31749 1/20 0.37
MYLK Q15746 1/20 0.37
MAPK14 Q16539 1/20 0.37
SRC P12931 1/20 0.37
PIK3CG P48736 2/20 0.37
KDM4A O75164 1/20 0.37
KDM5A P29375 1/20 0.37
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3297152 0.94 PTGDR2 (0.40) CCR4HRH4MEN1KMT2AEGFR
SCHEMBL3298444 0.93 CCR4 (0.47) CCR4HRH4
SCHEMBL3291434 0.93 CCR4 (0.40) CCR4HSD11B1HSD17B1HSD17B2EGFR
SCHEMBL3299632 0.93 CCR4 (0.40) CCR4HSD11B1HSD17B1HSD17B2EGFR
SCHEMBL3293882 0.93 CCR4 (0.38) CCR4HRH4HSD11B1HSD17B1HSD17B2
SCHEMBL3294557 0.92 CCR4 (0.38) CCR4HSD11B1HSD17B1HSD17B2EGFR
SCHEMBL3291319 0.91 HSD11B1 (0.41) CCR4HRH4HSD11B1HSD17B1HSD17B2
SCHEMBL3295746 0.91 HSD11B1 (0.41) CCR4HSD11B1HSD17B1HSD17B2EGFR
SCHEMBL3291749 0.91 EGFR (0.38) CCR4HSD11B1HSD17B1HSD17B2EGFR
SCHEMBL3291831 0.91 CCR4 (0.46) CCR4HSD11B1HSD17B1HSD17B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100266539-A1 CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2010-10-21 US disclosed
US-7732442-B2 Chemokine receptor antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-06-08 US disclosed
US-20070254886-A1 Chemokine Receptor Antagonist and Medical Use Thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-11-01 US disclosed
EP-1661889-A1 CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100266539-A1 CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF CCR5, CCR4, CCR1 CCR4 2/4885HRH4 76/4885HSD11B1 308/4885
US-20070254886-A1 Chemokine Receptor Antagonist and Medical Use Thereof CCR5, CCR4, CCR1 CCR4 2/4885HRH4 76/4885HSD11B1 308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.